Many people are unfamiliar with Postpartum Breast Cancer (PPBC), a little-known subset of breast cancer that occurs in women within 10 years of childbirth. This episode of our podcast delves into this personal topic for several members of our team.

Drs. Virginia Borges and Pepper Schedin are launching the first-ever clinical trial to prevent PPBC. Their groundbreaking approach involves giving healthy new mothers a brief course of ibuprofen as they wean their babies from breastfeeding. This trial holds huge potential for global impact, and the doctors need the public’s help to make it happen.

Our annual “We Remember” episode honors all who died from metastatic breast cancer since last October and gives voice to the grief and love that endures after each death. Each name shared is a tiny marker of a full, messy, beloved life and each one leaves behind an expansive network of loved ones.  For those of us in the MBC community, the loss of our friends is particularly devastating & the cumulative losses are heavy.  You are not alone in your grief.  We invite you to bear witness with us to this outpouring of love for those we have lost.

If you have been diagnosed with MBC bone metastases like the 3 hosts in this episode, this information is for you! Bone Mets are extremely common in MBC. In the first half of the episode, we explain the field of radiation oncology and all it covers, with Dr Kalnicki from Montefiore Einstein Comprehensive Cancer Center in Bronx, NY; in the second half we feature an interview with the leader of the Duke Center for Brain and Spine Metastasis. Duke’s approach to managing bone mets includes a comprehensive team of specialists that offer the traditional and some less commonly seen treatments, like Cryoablation (freezing) and Radiofrequency Ablation (heating) of tumors. We also cover emerging science in bone mets, like “Theranostics” which is having success in prostate cancers and may hold promise for MBC. So listen here and learn with us, and check out our show notes for the links to what’s covered in the episode.

If you don't hear much about the rising rates of all stages of breast cancer, including MBC, in young women, you're not alone. De novo MBC rates (when Stage 4 MBC is found at the first diagnosis) are rising "exponentially", and fastest among women between the ages of 25 and 39, but not in older women. These trends are alarming to researchers. Perhaps most shocking of all: half of young women diagnosed with breast cancer under 45 have a postpartum diagnosis, defined as being within 10 years from their youngest child's birth, and that is something that rarely gets covered or explained. We'll explore it all in this episode, including the possible causes, recommendations for testing and even contraception for young women, and the research and clinical leaders working to make this a top priority in the BC & MBC space. It's difficult to consider, and dense, we know. But so important and important to share with all the young women in our lives. Not to scare them, but to inform and empower them.

Over the last 20 years, advances in HER2 targeting treatments, antibody-drug conjugates (ADCs), immune checkpoint inhibitors (ICIs), and cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6is) have prolonged survival and changed the breast cancer treatment landscape. Success leads to more questions about optimal drug sequencing, mechanisms of resistance, and how to overcome that resistance. Let’s ask Dr. Stephanie Graff to help us tackle these topics and more.

There’s a FDA- approved diagnostic imaging agent developed to comprehensively evaluate estrogen receptor-positive (ER+) lesions in recurrent or metastatic breast cancer as an adjunct to biopsy. By creating a “whole-body” picture of ER+ lesions, Cerianna may be a helpful diagnostic tool in helping oncologists better determine the most appropriate course of treatment. Learn more in this episode.

All of us approach life and death in general from the perspective of our faith traditions, our family cultures, and the traditions and culture we choose as adults.